JO3126B1 - مثبطات ناقل نيوكليوسيد متوازن اي ان تي 1 - Google Patents

مثبطات ناقل نيوكليوسيد متوازن اي ان تي 1

Info

Publication number
JO3126B1
JO3126B1 JOP/2008/0435A JOP20080435A JO3126B1 JO 3126 B1 JO3126 B1 JO 3126B1 JO P20080435 A JOP20080435 A JO P20080435A JO 3126 B1 JO3126 B1 JO 3126B1
Authority
JO
Jordan
Prior art keywords
nucleoside transporter
equilibrative nucleoside
compounds
inhibitors
enti
Prior art date
Application number
JOP/2008/0435A
Other languages
English (en)
Inventor
Jean- Paul Rene Marie Andre Bosmans
Serge Maria Aloysius Pieters
Didier Jean-Claude Berthelot
Cleyn Michel Anna Jozef De
Bie Maria Pieter Verbist
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Application granted granted Critical
Publication of JO3126B1 publication Critical patent/JO3126B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

يتعلق الاختراع الحالي بمركبات ( COMPOUNDS) جديدة من الصيغه ( I) لها خواص تثبيط ( INHIBITING) ENTI ناقل ( TRANSPORTER) NUCLEOSIDE متوازن، بتركيبات دوائية ( PHRMAEUTICAL COMPOSITIONS) تشمل هذه المركبات بعمليات كيميائية ( CHEMICAL PROCESSES) من اجل تحضير هذه المركبات وباستخدامها في معالجة امراض مرتبطة بتثبيط مستقبلات ( RECEPTORS) ENTI في الحيوانات، على وجة الخصوص ادميين
JOP/2008/0435A 2007-11-14 2008-10-07 مثبطات ناقل نيوكليوسيد متوازن اي ان تي 1 JO3126B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07120630 2007-11-14

Publications (1)

Publication Number Publication Date
JO3126B1 true JO3126B1 (ar) 2017-09-20

Family

ID=39145373

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2008/0435A JO3126B1 (ar) 2007-11-14 2008-10-07 مثبطات ناقل نيوكليوسيد متوازن اي ان تي 1

Country Status (18)

Country Link
US (1) US8263592B2 (ar)
EP (1) EP2209790B1 (ar)
JP (1) JP5369108B2 (ar)
KR (1) KR101598136B1 (ar)
CN (1) CN101855224B (ar)
AR (1) AR069304A1 (ar)
AU (1) AU2008322960B2 (ar)
BR (1) BRPI0820642B1 (ar)
CA (1) CA2704423C (ar)
CL (1) CL2008003383A1 (ar)
EA (1) EA017215B1 (ar)
ES (1) ES2569511T3 (ar)
HK (1) HK1146722A1 (ar)
IL (1) IL205710A (ar)
JO (1) JO3126B1 (ar)
PA (1) PA8803401A1 (ar)
TW (1) TWI437000B (ar)
WO (1) WO2009062990A2 (ar)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201101959D0 (en) 2011-02-04 2011-03-23 Univ Nottingham Novel ether linked compoundsand improved treatments for cardiac and cardiovascular disease
PE20161476A1 (es) 2014-06-26 2017-01-07 Hoffmann La Roche Derivados de indolin-2-ona o pirrolo-piridin-2-ona
CN108349942B (zh) 2015-11-06 2021-03-30 豪夫迈·罗氏有限公司 用于治疗cns和相关疾病的二氢吲哚-2-酮衍生物
JP6857662B2 (ja) 2015-11-06 2021-04-14 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ インドリン−２−オン誘導体
EP3371174B1 (en) * 2015-11-06 2021-03-17 H. Hoffnabb-La Roche Ag Indolin-2-one derivatives
CN105802999B (zh) * 2016-04-01 2019-05-03 中南大学湘雅医院 一种膜蛋白ENTs跨膜转运ODNs的试剂盒及方法
JP6879677B2 (ja) 2016-05-26 2021-06-02 株式会社クボタ 作業車
TW201817726A (zh) 2016-11-14 2018-05-16 大陸商江蘇恆瑞醫藥股份有限公司 ３，４－二吡啶基吡唑類衍生物、其製備方法及其在醫藥上的應用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9701396D0 (sv) * 1997-04-15 1997-04-15 Astra Pharma Prod Compounds
GB0003397D0 (en) * 2000-02-14 2000-04-05 Merck Sharp & Dohme Therapeutic agents
WO2004060902A2 (en) 2002-12-31 2004-07-22 John K Buolamwini Novel nucleoside transport inhibitors
JPWO2004101593A1 (ja) * 2003-05-16 2006-07-13 キッセイ薬品工業株式会社 ５’−修飾ヌクレオシド誘導体及びその医薬用途
EP1698635B1 (en) * 2003-12-26 2011-12-14 Kissei Pharmaceutical Co., Ltd. Benzimidazole derivatives and medical uses thereof
US8083773B2 (en) * 2005-07-15 2011-12-27 Muhammad Abubakar Atiq Durrani Apparatus for minimally invasive posterior correction of spinal deformity
AR057570A1 (es) * 2005-11-14 2007-12-05 Solvay Pharm Gmbh Derivados de n-sulfamoil-n'-benzopiranopiperidinas espirocondensadas, composiciones farmaceuticas que los comprenden, un procedimiento para su preparacion y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por las isoenzimas anhidrasas carbonicas subtipos ii y/o
US7576207B2 (en) * 2006-04-06 2009-08-18 Adolor Corporation Spirocyclic heterocyclic derivatives and methods of their use

Also Published As

Publication number Publication date
TWI437000B (zh) 2014-05-11
CL2008003383A1 (es) 2010-02-05
US8263592B2 (en) 2012-09-11
EP2209790A2 (en) 2010-07-28
JP5369108B2 (ja) 2013-12-18
PA8803401A1 (es) 2009-06-23
US20100280025A1 (en) 2010-11-04
AU2008322960B2 (en) 2013-02-07
EA201070599A1 (ru) 2010-12-30
KR20100089088A (ko) 2010-08-11
EA017215B1 (ru) 2012-10-30
BRPI0820642A2 (pt) 2020-08-11
AU2008322960A1 (en) 2009-05-22
CA2704423C (en) 2017-01-10
WO2009062990A2 (en) 2009-05-22
EP2209790B1 (en) 2016-02-17
KR101598136B1 (ko) 2016-02-29
JP2011503147A (ja) 2011-01-27
ES2569511T3 (es) 2016-05-11
HK1146722A1 (en) 2011-07-08
CA2704423A1 (en) 2009-05-22
CN101855224A (zh) 2010-10-06
TW200936593A (en) 2009-09-01
WO2009062990A3 (en) 2009-09-24
BRPI0820642B1 (pt) 2021-05-25
CN101855224B (zh) 2012-11-28
AR069304A1 (es) 2010-01-13
IL205710A (en) 2013-07-31
IL205710A0 (en) 2010-11-30

Similar Documents

Publication Publication Date Title
JO3126B1 (ar) مثبطات ناقل نيوكليوسيد متوازن اي ان تي 1
UA96785C2 (uk) Заміщені похідні оксиндолу та їх застосування як лігандів рецептора вазопресину
MX2009004745A (es) Derivados de 1,2,3-triazol como inhibidores del receptor sigma.
UA95644C2 (ru) Пиридазиноновые производные, фармацевтическая композиция и способ лечения заболеваний
JO3007B1 (ar) مركبات و تركيبات كمثبطات كيناز بروتين
UA108743C2 (uk) Похідні хіназолін-4(3н)-ону для застосування як інгібіторів рі3-кінази
NI201000033A (es) Amidas heterocíclicas útiles para el tratamiento de cáncer y psoriasis
UA99524C2 (ru) Триазолопроизводные, полезные для лечения болезней
ATE520668T1 (de) Sigmarezeptor-inhibitoren
CY1110342T1 (el) Κανναβινοειδεις αγωνιστες βενζιμιδαζολης που φερουν μια υποκατεστημενη ετεροκυκλικη ομαδα
GEP20146197B (en) New compounds
ATE533762T1 (de) Chinolin- oder isochinolinsubstituierte p2x7- antagonisten
UA109667C2 (xx) Похідні хіназолін-4(3h)-ону, що використовуються як інгібітори pi3-кінази
WO2009071631A3 (en) Dibenzoazepine and dibenzooxazepine trpa1 agonists
NZ590650A (en) Buprenorphine analogs
TN2012000534A1 (en) Pyrazole compounds as sigma receptor inhibitors
MY165113A (en) Piperidinone carboxamide azaindane cgrp receptor antagonists
MX2012001838A (es) Compuestos de hidrazona heterociclico y sus usos para tratar cancer e inflamacion.
DE602008001725D1 (de) 1-(1-benzylpiperidin-4-yl)benzimidazol-5-carbonsäurederivate zur behandlung von diabetes mellitus
EP2091328A4 (en) SPIROPIPERIDININHIBITORS OF BETA-SECRETASE FOR THE TREATMENT OF ALZHEIMER DISEASE
MX2010007584A (es) Inhibidores de proteina cinasa y uso de los mismos.
MY167898A (en) Co-crystals and salts of ccr3-inhibitors
UA107183C2 (uk) Феніламіно-ізонікотинамідні сполуки, їх застосування, фармацевтична композиція, що їх містить, та спосіб лікування гіперпроліферативних захворювань
MX2009006473A (es) Inhibidores de receptor vainilloide de bencimidazol.
MX2011013869A (es) Agentes antihelminticos y su uso.